摘要:
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.
摘要:
Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R2, R3, R4, R5 and R6 independently of one another are hydrogen; OH; C1-C30alkyl, C2-C30al- kenyl, C1-C30alkoxy, C3-C12cycloalkyl or C1C30hydroxyalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C6-C20aryl, which may be substitu¬ ted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G, C2- C18alkenyl, C2-C18alkynyl, C7-C25aralkyl, CN, or -CO-R17; C1-C30mono- or dialkylamino; COR9; COOR9; CONR9R10; CN; SO2R9; OCOOR9; OCOR9; NHCOOR9; NR9COR10; NH2; *-(CO)-NH-(CH2)n1-(PO)-(OR11)2; -(CO)-O-(CH2)n1-(PO)-(OR11)2; sulphate; sulphonate; phosphate; phosphonate; -(CH2)n2-[O-(SO2)]n3-OR11; -O-(CH2)n4(CO)n5-R11; -(O)n6-(CH2)n7-(PO)-(OR9)2; -(O)n6-(CH2)n7-SO2-OR9; halogen; organosilanyl; organo- siloxanyl; or a sugar residue linked directly in an a- or ß-mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar- (CH2)n-(X1)1 or 0 -benzotropolone system, wherein n = 1 -10 and X1 = -0-; -(CO)-; -0-C0-; -COO-, -NH-; -S-; -SO2-); R1, R7 and R8 independently of one another are hydrogen; C1C12alkyl or C3-C12-cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C6- C20aryl, which may be substituted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G, C2-C18alkenyl, C2-C18alkynyl, C7-C25aralkyl, or COOR9; COR9; CONR9R10; SO3R9; SO2R9; PO3(R9)2; PO2(R9)2; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an a- or ß-mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH2)n-(X2)1 or 0-*, wherein n = 1 -10 and X2 = -C(=0)-; -0-C0-*); R9 and R10 independently from each other are hydrogen; C1C18alkyl or C3-C12-cycloalkyl which may be substituted by one or more E and/or interrupted by one or more D; C6- C20aryl, which may be substituted by one or more G; C4-C20heteroaryl, which may be substituted by one or more G; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an a- or ß-mode via the anomeric oxygen or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar- (CH2)n-*, wherein n = 1 -10); or R9 and R10 together form a five or six membered ring, R11 is hydrogen; or C1-C5alkyl; n1, n2, n4 and n7 independently from each other are a number from 1 to 5; n3, n5 and n6 independently from each other are a 0; or 1; D is -CO-; -COO-; -S-; -SO-; -SO2-; -O-; -NR14-; -S1R19R20-; -POR11-; -CR12=CR13-; or -C=C-; and E is -0R18; -SR18; -NR14R15; -NR14COR15; -C0R17; -COOR16; -CONR14R15; -CN; halogen; Or SO3R18; SO2R18; PO3(R18)2; PO2(R18)2; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an a- or ß-mode via the anomeric oxygen or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar- (CH2)n-(X1)1 or 0-*, wherein n = 1 -10 and X1 = -0-; -C(=0)-; -0-C0-; -COO-; -NH-; -S-; -SO2-); G is E; C1-C18alkyl, which is optionally interrupted by D; C1-C18perfluoroalkyl; C1-C18alkoxy, which is optionally substituted by E and/or interrupted by D; wherein R12, R13, R14 and R15 independently of each other are hydrogen; C6-C18aryl which is optionally substituted by OH, C1-C18alkyl or C1-C18alkoxy; C1-C18alkyl, which is optionally interrupted by -O-; or Ri4 and Ri5 together form a five or six membered ring, Ri6 is hydrogen; C6-Ci8aryl which is optionally substituted by OH, C1-C18alkyl or d- C18alkoxy; C1-C18alkyl which is optionally interrupted by -O-; R17 is H; C6-C18aryl which is optionally substituted by OH, C1-C18alkyl or C1-C18alkoxy; or d- C18alkyl which is optionally interrupted by -O-; R18 is hydrogen; C6-C18aryl, which is optionally substituted by OH, C1-C18alkyl or d- C18alkoxy; C1-C18alkyl, which is optionally interrupted by -O-; R19 and R20 independently of each other are hydrogen; C1-C18alkyl; C6-C18aryl which is optionally substituted by C1-C18alkyl; and R21 is C1-C18alkyl; or C6-C18aryl, which is substituted by C1-C18alkyl; * means, that this radical is directed to the benzotropolone moiety; for the protection of human and animal hair and skin against UV radiation.
摘要:
The preparation of an intermediate, a process for the preparation thereof and the process of preparing [4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-2-methyl-phenoxy]-acetic acid using this intermediate are described.
摘要:
This invention is concerned with compounds of the formula (I) wherein one of R 5 , R 6 and R 7 is formula (II) and X 1 , X 2 , R 1 to R 12 , m, n and o are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARd and/or PPARa agonists.